An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of DA-5210 10/500mg in Healthy Subjects at Fed State
Latest Information Update: 07 Jun 2022
At a glance
- Drugs DA-5210 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Dong-A ST
- 02 Jun 2022 Status changed from not yet recruiting to completed.
- 02 Nov 2021 New trial record